^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HHLA2 positive

    i
    Other names: HHLA2, HERV-H LTR-Associating 2, B7-H5, B7-H7, B7H7, B7y, Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2, HERV-H LTR-Associating Protein 2
    Entrez ID:
    11148
    Related biomarkers:
    Expression
    almost2years
    Clinical Value of Human Endogenous Retrovirus-H Long Terminal Repeat Associating 2 (HHLA2) in Small Cell Lung Cancer. (PubMed, Technol Cancer Res Treat)
    HHLA2-positive SCLC patients had higher tumour stages and shorter 2-year survival times than HHLA2-negative patients did. The new immune molecule HHLA2 may be an ideal clinical biomarker for predicting SCLC progression and could serve as a new immunotherapy target in SCLC.
    Journal • IO biomarker
    |
    HHLA2 (HERV-H LTR-Associating 2)
    |
    HHLA2 overexpression • HHLA2 positive
    almost3years
    Overexpression and Role of HHLA2, a Novel Immune Checkpoint, in Colorectal Cancer. (PubMed, Int J Mol Sci)
    We reveal the role of HHLA2 expression as well as a stimulatory and inhibitory immune checkpoint in colorectal cancer. Further research may verify the therapeutic values of the HHLA2-KIR3DL3/TMIGD2 pathway in colorectal cancer.
    Journal
    |
    MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • HHLA2 (HERV-H LTR-Associating 2)
    |
    HHLA2 overexpression • HHLA2 positive
    almost3years
    Expression pattern and clinicopathological implication of B7 family immune checkpoints, VTCN1 and HHLA2, in non-small cell lung cancer (AACR 2023)
    VTCN1 and HHLA2 are frequently co-expressed in PD-L1-negative NSCLC, especially EGFR-mutant LUAD rich in CD8+ T-cells and can serve as potential novel immunotherapeutic targets.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • HHLA2 (HERV-H LTR-Associating 2)
    |
    PD-L1 expression • EGFR mutation • EGFR expression • EGFR wild-type • PD-L1 negative • EGFR positive • EGFR negative • VTCN1 underexpression • HHLA2 positive